4//SEC Filing
Evans John M. 4
Accession 0000950170-25-012304
CIK 0001745999other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 4:05 PM ET
Size
9.5 KB
Accession
0000950170-25-012304
Insider Transaction Report
Form 4
Evans John M.
DirectorCEO
Transactions
- Sale
Common Stock
2025-01-30$26.75/sh−29,800$797,028→ 908,859 total - Sale
Common Stock
2025-01-30$27.28/sh−200$5,456→ 908,659 total - Award
Stock Option (Right to Buy)
2025-01-31+155,000→ 155,000 totalExercise: $25.92Exp: 2035-01-31→ Common Stock (155,000 underlying)
Holdings
- 103,000(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $26.26 to $27.21 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.
Documents
Issuer
Beam Therapeutics Inc.
CIK 0001745999
Entity typeother
Related Parties
1- filerCIK 0001786304
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 4:05 PM ET
- Size
- 9.5 KB